Endo Pharmacauticals has discontinued XIAFLEX injection in Australia and Asia,

[DrNewman]

Endo Pharmacauticals has discontinued XIAFLEX ,Collagenase Clostridium Histolyticum (CCH) injection in Australia and Asia, and plans to do the same to whole Europe by the end of 2019. The American laboratory has decided to withdraw it for economic reasons. As a result, the drug is no longer available except in the US and Canada. Now the only treatment options for Peyronie´s disease are surgery or Penile Traction Device (alone or combined with PRP), in the rest of the world. See official letter:

"Dear Healthcare Professional

This letter is to inform you that Sobi will discontinue the commercialisation of XIAPEX by the end of 2019.

XIAPEX is a product owned by Endo Ventures Limited (‘Endo’). Currently, XIAPEX is commercialised in the EU and other European and Middle Eastern countries by Sobi. Endo and Sobi have agreed to terminate the cooperation agreement for Xiapex effective December 31, 2019. The decision to withdraw is not based on safety or efficacy concerns.

Endo and Sobi are committed to managing the de-registration of Xiapex from the Sobi territories in an ethical and transparent manner and Sobi will process the withdrawal of the EU Marketing Authorisation, which will be effective from 1 March, 2020.

Please be assured that the wellbeing of patients during the discontinuation process is of paramount importance to Sobi and we are committed to the safety and comfort of all patients during the process of transition to other therapies. We want to emphasize that, subject to product availability from our supplier, Sobi is committed to providing XIAPEX up until the end of 2019.

We would like to thank you for your interest in XIAPEX over the years and deeply regret any inconvenience this may cause you.

If you have any questions or concerns, please do not hesitate to contact us at your convenience.

After de-registration, all enquiries, questions or requests for Named Patient Use of Xiapex must be referred directly to Endo. Contact endo.com/contact

Yours Sincerely,

Business Unit Director

Sobi